Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
ImmunoGen appoints Stacy Coen as Chief Business Officer » 08:21
06/01/20
06/01
08:21
06/01/20
08:21
IMGN

ImmunoGen

$4.69 /

-0.11 (-2.29%)

ImmunoGen announced that…

ImmunoGen announced that Stacy Coen has been appointed Senior Vice President and Chief Business Officer. The company said in a release, "Ms. Coen brings over 20 years of business and corporate development experience from leading oncology and rare disease companies. She joins ImmunoGen from Editas Medicine, where she served as Vice President, Business Development and was responsible for business development, strategy, transactions, and alliance management."

ShowHide Related Items >><<
IMGN ImmunoGen
$4.69 /

-0.11 (-2.29%)

IMGN ImmunoGen
$4.69 /

-0.11 (-2.29%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
IMGN ImmunoGen
$4.69 /

-0.11 (-2.29%)

IMGN ImmunoGen
$4.69 /

-0.11 (-2.29%)

Hot Stocks
ImmunoGen announces initial data from FORWARD II study at ASCO » 08:32
05/29/20
05/29
08:32
05/29/20
08:32
IMGN

ImmunoGen

$4.80 /

-0.07 (-1.44%)

ImmunoGen announced…

ImmunoGen announced initial data from the FORWARD II study evaluating mirvetuximab soravtansine in combination with Avastin in patients with medium and high folate receptor alpha, or FRa-expressing, recurrent ovarian cancer for whom a non-platinum based combination regimen is appropriate. These findings were presented in an oral presentation at the American Society of Clinical Oncology, or ASCO. The cohort enrolled 60 patients with a median age of 60 and a median number of two prior lines of therapy. Thirty-two patients had platinum-resistant disease with a platinum-free interval, or PFI, of less than or equal to six months; 28 patients had platinum-sensitive disease - of which 20 patients had a PFI greater than six months and less than or equal to 12 months and 8 patients (13%) had a PFI greater than 12 months. The combination of mirvetuximab with bevacizumab in this cohort demonstrates promising anti-tumor activity with a favorable tolerability profile, particularly among patients with high levels of FRa expression. In the overall patient population, objective responses were seen in 28 patients and the confirmed overall response rate, or ORR, was 47%. In patients with high FRa expression, the confirmed ORR was 64%, with an ORR of 59% in the platinum-resistant subgroup and 69% in the platinum-sensitive subgroup. With a median follow-up of 8.5 months and nearly half of patients with high FRa expression remaining on study, the duration of response and progression-free survival data are immature. The adverse events, or AEs, observed with the doublet were manageable and consistent with the side effect profiles of each agent. The most common treatment-related AEs were low-grade, including diarrhea, blurred vision, fatigue, and nausea; grade 3+ AEs were infrequent.

ShowHide Related Items >><<
IMGN ImmunoGen
$4.80 /

-0.07 (-1.44%)

IMGN ImmunoGen
$4.80 /

-0.07 (-1.44%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
IMGN ImmunoGen
$4.80 /

-0.07 (-1.44%)

IMGN ImmunoGen
$4.80 /

-0.07 (-1.44%)

Conference/Events
RBC Capital to hold a virtual conference » 04:55
05/20/20
05/20
04:55
05/20/20
04:55
ADUS

Addus HomeCare

$89.04 /

-0.89 (-0.99%)

, HOOK

Hookipa Pharma

$9.27 /

-0.88 (-8.67%)

, KPTI

Karyopharm

$17.68 /

-0.97 (-5.20%)

, UHS

Universal Health

$101.01 /

+0.55 (+0.55%)

, ENTA

Enanta

$54.33 /

-3.25 (-5.64%)

, REGN

Regeneron

$557.61 /

-1.76 (-0.31%)

, ARAV

Aravive

$12.27 /

-0.31 (-2.46%)

, IMGN

ImmunoGen

$4.62 /

-0.14 (-2.94%)

, HCA

HCA Healthcare

$103.94 /

-1.63 (-1.54%)

, PFE

Pfizer

$37.68 /

-0.4 (-1.05%)

, BCEL

Atreca

$18.06 /

-0.69 (-3.68%)

, JAZZ

Jazz Pharmaceuticals

$113.07 /

-3.23 (-2.78%)

, OVID

Ovid Therapeutics

$4.46 /

+0.29 (+6.95%)

, ACAD

Acadia

$51.02 /

-1.05 (-2.02%)

, BMRN

BioMarin

$93.88 /

-1.46 (-1.53%)

, EHTH

eHealth

$124.65 /

-2.38 (-1.87%)

, EXEL

Exelixis

$24.87 /

-0.79 (-3.08%)

, INO

Inovio

$14.56 /

+0.41 (+2.90%)

, SPRT

Support.com

$1.25 /

-0.01 (-0.79%)

, CYH

Community Health

$3.11 /

-0.05 (-1.58%)

, INCY

Incyte

$94.92 /

-1.58 (-1.64%)

, AGIO

Agios Pharmaceuticals

$47.89 /

-0.93 (-1.90%)

, EGRX

Eagle Pharmaceuticals

$53.24 /

-1.26 (-2.31%)

, IGMS

IGM Biosciences

$52.75 /

-2.66 (-4.80%)

, AIMT

Aimmune

$16.55 /

-0.92 (-5.27%)

, VRCA

Verrica Pharmaceuticals

$10.11 /

-0.62 (-5.78%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$101.01 /

+0.55 (+0.55%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$54.33 /

-3.25 (-5.64%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$557.61 /

-1.76 (-0.31%)

05/19/20 Roth Capital
Rapt CCR4 antagonist may be competitive against Dupixent, says Roth Capital
05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
ARAV Aravive
$12.27 /

-0.31 (-2.46%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$37.68 /

-0.4 (-1.05%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.06 /

-0.69 (-3.68%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$51.02 /

-1.05 (-2.02%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$124.65 /

-2.38 (-1.87%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.56 /

+0.41 (+2.90%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.25 /

-0.01 (-0.79%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$94.92 /

-1.58 (-1.64%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.11 /

-0.62 (-5.78%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

OVID Ovid Therapeutics
$4.46 /

+0.29 (+6.95%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

IGMS IGM Biosciences
$52.75 /

-2.66 (-4.80%)

HOOK Hookipa Pharma
$9.27 /

-0.88 (-8.67%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

ENTA Enanta
$54.33 /

-3.25 (-5.64%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

EGRX Eagle Pharmaceuticals
$53.24 /

-1.26 (-2.31%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

BCEL Atreca
$18.06 /

-0.69 (-3.68%)

ARAV Aravive
$12.27 /

-0.31 (-2.46%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

ADUS Addus HomeCare
$89.04 /

-0.89 (-0.99%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

AGIO Agios Pharmaceuticals
$47.89 /

-0.93 (-1.90%)

UHS Universal Health
$101.01 /

+0.55 (+0.55%)

SPRT Support.com
$1.25 /

-0.01 (-0.79%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

KPTI Karyopharm
$17.68 /

-0.97 (-5.20%)

JAZZ Jazz Pharmaceuticals
$113.07 /

-3.23 (-2.78%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

IMGN ImmunoGen
$4.62 /

-0.14 (-2.94%)

HCA HCA Healthcare
$103.94 /

-1.63 (-1.54%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

REGN Regeneron
$557.61 /

-1.76 (-0.31%)

PFE Pfizer
$37.68 /

-0.4 (-1.05%)

INO Inovio
$14.56 /

+0.41 (+2.90%)

INCY Incyte
$94.92 /

-1.58 (-1.64%)

EXEL Exelixis
$24.87 /

-0.79 (-3.08%)

EHTH eHealth
$124.65 /

-2.38 (-1.87%)

CYH Community Health
$3.11 /

-0.05 (-1.58%)

BMRN BioMarin
$93.88 /

-1.46 (-1.53%)

AIMT Aimmune
$16.55 /

-0.92 (-5.27%)

ACAD Acadia
$51.02 /

-1.05 (-2.02%)

Conference/Events
RBC Capital to hold a virtual conference » 08:45
05/19/20
05/19
08:45
05/19/20
08:45
ADUS

Addus HomeCare

$89.93 /

+5.99 (+7.14%)

, HOOK

Hookipa Pharma

$10.15 /

+0.78 (+8.32%)

, KPTI

Karyopharm

$18.65 /

-0.4 (-2.10%)

, UHS

Universal Health

$100.46 /

+7.86 (+8.49%)

, ENTA

Enanta

$57.58 /

+2.25 (+4.07%)

, REGN

Regeneron

$559.37 /

-16.71 (-2.90%)

, ARAV

Aravive

$12.58 /

+0.11 (+0.88%)

, IMGN

ImmunoGen

$4.76 /

+0.33 (+7.45%)

, HCA

HCA Healthcare

$105.57 /

+6.83 (+6.92%)

, PFE

Pfizer

$38.08 /

+0.31 (+0.82%)

, BCEL

Atreca

$18.75 /

-0.44 (-2.29%)

, JAZZ

Jazz Pharmaceuticals

$116.30 /

+4.79 (+4.30%)

, OVID

Ovid Therapeutics

$4.17 /

+0.09 (+2.21%)

, ACAD

Acadia

$52.07 /

+1.23 (+2.42%)

, BMRN

BioMarin

$95.34 /

+1.595 (+1.70%)

, EHTH

eHealth

$127.03 /

+9.13 (+7.74%)

, EXEL

Exelixis

$25.66 /

-0.07 (-0.27%)

, INO

Inovio

$14.15 /

+0.73 (+5.44%)

, SPRT

Support.com

$1.26 /

+0.06 (+5.00%)

, CYH

Community Health

$3.16 /

+0.435 (+15.99%)

, INCY

Incyte

$96.50 /

+0.37 (+0.38%)

, AGIO

Agios Pharmaceuticals

$48.82 /

+2.38 (+5.12%)

, EGRX

Eagle Pharmaceuticals

$54.50 /

+1.74 (+3.30%)

, IGMS

IGM Biosciences

$55.41 /

-3.59 (-6.08%)

, AIMT

Aimmune

$17.47 /

+1.1 (+6.72%)

, VRCA

Verrica Pharmaceuticals

$10.73 /

+0.47 (+4.58%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference will be held on May 19-20.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

03/20/20 RBC Capital
RBC says Addus HomeCare selloff unwarranted as lockdowns don't apply
12/10/19 Oppenheimer
Addus HomeCare price target raised to $107 from $96 at Oppenheimer
11/21/19 RBC Capital
Addus HomeCare price target raised to $109 from $100 at RBC Capital
11/06/19 RBC Capital
Addus HomeCare price target raised to $100 from $90 at RBC Capital
HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
UHS Universal Health
$100.46 /

+7.86 (+8.49%)

04/29/20 Deutsche Bank
Universal Health price target lowered to $135 from $165 at Deutsche Bank
04/28/20 Citi
Universal Health price target lowered to $128 from $157 at Citi
03/26/20 JPMorgan
Channel checks suggest hospital total revenues down 40%-60%, says JPMorgan
03/23/20 BofA
Universal Health downgraded to Neutral on Vegas recession risk at BofA
ENTA Enanta
$57.58 /

+2.25 (+4.07%)

03/17/20 Baird
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'
03/17/20 Baird
Enanta upgraded to Outperform from Neutral at Baird
02/07/20 Roth Capital
Enanta is 'undervalued and underappreciated,' says Roth Capital
11/22/19
Fly Intel: Top five analyst downgrades
REGN Regeneron
$559.37 /

-16.71 (-2.90%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
ARAV Aravive
$12.58 /

+0.11 (+0.88%)

04/30/20 Piper Sandler
Aravive partnering with WuXi to develop CCN2 antibodies, says Piper Sandler
03/27/20 H.C. Wainwright
Aravive price target lowered to $15 from $25 at H.C. Wainwright
02/18/20 Piper Sandler
IDMC recommends dose escalation in Aravive trial, says Piper Sandler
01/13/20 Piper Sandler
Piper Sandler reiterated Overweight on Aravive after AVB-500 expansion
IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

04/27/20 UBS
HCA Healthcare price target lowered to $138 from $183 at UBS
04/22/20 SunTrust
HCA Healthcare price target lowered to $140 from $160 at SunTrust
04/22/20 Deutsche Bank
HCA Healthcare price target lowered to $132 from $165 at Deutsche Bank
04/22/20 Oppenheimer
HCA Healthcare price target lowered to $135 from $160 at Oppenheimer
PFE Pfizer
$38.08 /

+0.31 (+0.82%)

05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
05/15/20 William Blair
Sarepta maintains leadership position after Pfizer data, says William Blair
BCEL Atreca
$18.75 /

-0.44 (-2.29%)

04/22/20 H.C. Wainwright
Atreca initiated with a Buy at H.C. Wainwright
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/21/20 Wedbush
Atreca initiated with an Outperform at Wedbush
04/15/20 Baird
Atreca initiated with an Outperform at Baird
JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

05/06/20 SVB Leerink
Jazz Pharmaceuticals price target lowered to $160 from $169 at SVB Leerink
05/06/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $132 from $141 at Oppenheimer
05/06/20 BMO Capital
Jazz Pharmaceuticals price target lowered to $193 from $205 at BMO Capital
05/06/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $113 from $127 at Piper Sandler
OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
09/23/19 Piper Sandler
Piper says Ovid shares reflect little value for 'exciting' soticlestat program
ACAD Acadia
$52.07 /

+1.23 (+2.42%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 Jefferies
Acadia initiated with a Buy at Jefferies
04/03/20 Piper Sandler
Acadia one of the safer names to own right now, says Piper Sandler
03/31/20 Goldman Sachs
Acadia upgraded to Buy from Neutral at Goldman Sachs
BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
EHTH eHealth
$127.03 /

+9.13 (+7.74%)

05/14/20 Raymond James
Raymond James says eHealth accounting more conservative than some peers
05/14/20 Craig-Hallum
CMS' SEP to be like new Easter season for eHealth, says Craig-Hallum
04/29/20 Cantor Fitzgerald
Humana comments on telephonic sales 'positive' for eHealth, says Cantor
04/24/20 SunTrust
eHealth's path to over 50% growth has been made easier, says SunTrust
EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
INO Inovio
$14.15 /

+0.73 (+5.44%)

04/30/20 Roth Capital
Inovio downgraded to Neutral from Buy at Roth Capital
04/29/20 Cantor Fitzgerald
Inovio price target raised to $17 from $13 at Cantor Fitzgerald
04/29/20 H.C. Wainwright
Inovio COVID-19 vaccine could be used across globe, says H.C. Wainwright
04/29/20 Stifel
Stifel more than doubles Inovio target to $19, sees favorable setup
SPRT Support.com
$1.26 /

+0.06 (+5.00%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

02/24/20 RBC Capital
Community Health price target raised to $8 from $4 at RBC Capital
02/20/20 Raymond James
Community Health upgraded at Raymond James as near-term pressures limited
02/20/20 Raymond James
Community Health upgraded to Market Perform from Underperform at Raymond James
INCY Incyte
$96.50 /

+0.37 (+0.38%)

05/19/20 Cantor Fitzgerald
Incyte price target raised to $100 from $83 at Cantor Fitzgerald
05/06/20 Piper Sandler
Incyte approval of Tabrecta came soon than expected, says Piper Sandler
05/06/20
Fly Intel: Top five analyst downgrades
05/06/20 Oppenheimer
Incyte price target raised to $120 from $112 at Oppenheimer
AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

05/11/20 Piper Sandler
Agios Pharmaceuticals should be bought now, says Piper Sandler
05/04/20 JPMorgan
Agios Pharmaceuticals price target raised to $82 from $72 at JPMorgan
04/30/20 Piper Sandler
Agios' beta thal, sickle cell data should be positive, says Piper Sandler
03/04/20 Barclays
Agios Pharmaceuticals initiated with an Equal Weight at Barclays
EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
05/08/20 Piper Sandler
IGM Biosciences price target raised to $81 from $53 at Piper Sandler
04/22/20 Wedbush
Wedbush bullish on IGM Biosciences, initiates with an Outperform
AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

05/13/20 Credit Suisse
Aimmune price target lowered to $19 from $29 at Credit Suisse
05/12/20 H.C. Wainwright
Aimmune price target lowered to $15 from $30 at H.C. Wainwright
05/12/20 Stifel
Aimmune price target lowered to $20 from $32 at Stifel
05/11/20 Piper Sandler
Uptake of Aimmune's Palforzia to remain slow, says Piper Sandler
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
03/23/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
11/27/19 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $23 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$10.73 /

+0.47 (+4.58%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

OVID Ovid Therapeutics
$4.17 /

+0.09 (+2.21%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

IGMS IGM Biosciences
$55.41 /

-3.59 (-6.08%)

HOOK Hookipa Pharma
$10.15 /

+0.78 (+8.32%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

ENTA Enanta
$57.58 /

+2.25 (+4.07%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

EGRX Eagle Pharmaceuticals
$54.50 /

+1.74 (+3.30%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

BCEL Atreca
$18.75 /

-0.44 (-2.29%)

ARAV Aravive
$12.58 /

+0.11 (+0.88%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

ADUS Addus HomeCare
$89.93 /

+5.99 (+7.14%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

AGIO Agios Pharmaceuticals
$48.82 /

+2.38 (+5.12%)

UHS Universal Health
$100.46 /

+7.86 (+8.49%)

SPRT Support.com
$1.26 /

+0.06 (+5.00%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

KPTI Karyopharm
$18.65 /

-0.4 (-2.10%)

JAZZ Jazz Pharmaceuticals
$116.30 /

+4.79 (+4.30%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

IMGN ImmunoGen
$4.76 /

+0.33 (+7.45%)

HCA HCA Healthcare
$105.57 /

+6.83 (+6.92%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

REGN Regeneron
$559.37 /

-16.71 (-2.90%)

PFE Pfizer
$38.08 /

+0.31 (+0.82%)

INO Inovio
$14.15 /

+0.73 (+5.44%)

INCY Incyte
$96.50 /

+0.37 (+0.38%)

EXEL Exelixis
$25.66 /

-0.07 (-0.27%)

EHTH eHealth
$127.03 /

+9.13 (+7.74%)

CYH Community Health
$3.16 /

+0.435 (+15.99%)

BMRN BioMarin
$95.34 /

+1.595 (+1.70%)

AIMT Aimmune
$17.47 /

+1.1 (+6.72%)

ACAD Acadia
$52.07 /

+1.23 (+2.42%)

On The Fly
Fly Intel: After-Hours Movers » 19:04
05/13/20
05/13
19:04
05/13/20
19:04
KNSA

Kiniksa

$18.97 /

-2.13 (-10.09%)

, ARVN

Arvinas

$51.00 /

-4.4 (-7.94%)

, SDC

SmileDirectClub

$7.70 /

-0.39 (-4.82%)

, JACK

Jack in the Box

$63.59 /

-2.29 (-3.48%)

, VRTU

Virtusa

$31.75 /

-1.95 (-5.79%)

, ONEM

1Life Healthcare

$26.78 /

-0.44 (-1.62%)

, PANL

Pangaea Logistics

$2.30 /

-0.03 (-1.29%)

, FCAU

Fiat Chrysler

$7.90 /

-0.27 (-3.30%)

, MA

MasterCard

$269.58 /

-2.66 (-0.98%)

, IMGN

ImmunoGen

$4.09 /

-0.19 (-4.44%)

, ALLO

Allogene Therapeutics

$30.99 /

-1.56 (-4.79%)

, IMUX

Immunic

$10.00 /

-0.72 (-6.72%)

, OII

Oceaneering

$4.64 /

-0.26 (-5.31%)

, FLO

Flowers Foods

$22.64 /

+0.17 (+0.76%)

, CSCO

Cisco

$41.91 /

-1.28 (-2.96%)

, RVLV

Revolve Group

$14.92 /

+0.49 (+3.40%)

, BRP

BRP Group

$8.99 /

-1.01 (-10.10%)

, JAKK

JAKKS Pacific

$0.59 /

-0.0939 (-13.81%)

, RKDA

Arcadia Biosciences

$4.88 /

+0.15 (+3.17%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VRTU Virtusa
$31.75 /

-1.95 (-5.79%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

RKDA Arcadia Biosciences
$4.88 /

+0.15 (+3.17%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

OII Oceaneering
$4.64 /

-0.26 (-5.31%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

FLO Flowers Foods
$22.64 /

+0.17 (+0.76%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

BRP BRP Group
$8.99 /

-1.01 (-10.10%)

ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

05/13/20 Piper Sandler
Arvinas pullback represents a buying opportunity, says Piper Sandler
05/13/20 Wedbush
Arvinas removed from Best Ideas List at Wedbush
05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Oppenheimer
Arvinas initiated with a Perform at Oppenheimer
SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

04/07/20 Goldman Sachs
SmileDirectClub downgraded to Sell from Neutral at Goldman Sachs
04/06/20 Guggenheim
SmileDirectClub removed from Best Ideas list at Guggenheim
03/02/20
Fly Intel: Top five analyst downgrades
03/02/20 UBS
SmileDirectClub downgraded to Neutral from Buy at UBS
JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

05/11/20 SunTrust
Jack in the Box price target raised to $79 from $66 at SunTrust
04/16/20 SunTrust
Jack in the Box price target raised to $66 from $49 at SunTrust
04/16/20 Wells Fargo
Jack in the Box price target lowered to $72 from $105 at Wells Fargo
04/16/20 Oppenheimer
Jack in the Box price target lowered to $70 from $96 at Oppenheimer
VRTU Virtusa
$31.75 /

-1.95 (-5.79%)

02/07/20 Needham
Virtusa price target raised to $56 from $48 at Needham
01/07/20 Barrington
Adtalem, Tivity, Virtusa among Barrington's Best Ideas for 2020
01/06/20 Wedbush
Wedbush says buy Virtusa on weakness as market 'overreacts' to Citi renewal
01/06/20 Wedbush
Virtusa pullback on Citi renewal news a buying opportunity, says Wedbush
ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

02/25/20 Morgan Stanley
1Life Healthcare initiated with an Overweight at Morgan Stanley
02/25/20 JPMorgan
1Life Healthcare initiated with an Overweight at JPMorgan
02/25/20 SunTrust
1Life Healthcare initiated with a Buy at SunTrust
02/25/20 Citi
1Life Healthcare initiated with a Neutral at Citi
PANL Pangaea Logistics
$2.30 /

-0.03 (-1.29%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

03/24/20 UBS
Tesla and BMW upgraded, Ford downgraded at UBS
03/11/20 Morgan Stanley
Morgan Stanley cuts estimates for GM, Ford and FCA on coronavirus 'demand shock'
12/18/19 Evercore ISI
Evercore ISI upgrades Fiat Chrysler to Outperform after Peugeot deal formalized
12/18/19 Evercore ISI
Fiat Chrysler upgraded to Outperform from In Line at Evercore ISI
MA MasterCard
$269.58 /

-2.66 (-0.98%)

05/06/20 Stephens
Visa franchises will exit recession stronger, says Stephens
05/06/20 Stephens
MasterCard price target raised to $304 from $286 at Stephens
05/04/20 BMO Capital
Visa price target lowered to $213 from $234 at BMO Capital
04/30/20 RBC Capital
MasterCard price target raised to $308 from $287 at RBC Capital
IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

05/13/20 H.C. Wainwright
Allogene's TurboCARs shows promise for solid tumors, says H.C. Wainwright
04/13/20
Fly Intel: Top five analyst initiations
04/13/20 SunTrust
Allogene Therapeutics initiated with a Buy at SunTrust
04/13/20 SunTrust
Allogene Therapeutics initiated with a Buy at SunTrust
IMUX Immunic
$10.00 /

-0.72 (-6.72%)

05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
03/25/20
Fly Intel: Top five analyst initiations
03/25/20 Roth Capital
Immunic initiated with a Buy at Roth Capital
OII Oceaneering
$4.64 /

-0.26 (-5.31%)

04/24/20 Citi
Oceaneering upgraded to Buy from Neutral at Citi
04/05/20 Bernstein
Oceaneering upgraded to Market Perform from Underperform at Bernstein
03/19/20 Wolfe Research
Oceaneering downgraded to Peer Perform from Outperform at Wolfe Research
03/13/20 Wells Fargo
Drillers downgraded at Wells Fargo on recent sell off in commodity prices
FLO Flowers Foods
$22.64 /

+0.17 (+0.76%)

01/22/20 Jefferies
Flowers Foods initiated with a Hold at Jefferies
01/22/20 Jefferies
Flowers Foods initiated with a Hold at Jefferies
12/11/19 Deutsche Bank
Flowers Foods resumed with a Hold at Deutsche Bank
12/11/19 Deutsche Bank
Flowers Foods resumed with a Hold at Deutsche Bank
CSCO Cisco
$41.91 /

-1.28 (-2.96%)

04/17/20 KeyBanc
Cisco downgraded to Sector Weight from Overweight at KeyBanc
04/16/20 Cleveland Research
Cisco dips after Cleveland Research calls out partners' worsening trends
04/14/20 MKM Partners
Cisco price target lowered to $40 from $48 at MKM Partners
04/06/20 Raymond James
Cisco price target lowered to $48 from $54 at Raymond James
RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

03/19/20
Fly Intel: Top five analyst downgrades
03/19/20 Jefferies
Jefferies cuts Revolve Group to Hold, lowers price target to $9
03/19/20 Jefferies
Revolve Group downgraded to Hold from Buy at Jefferies
03/18/20 Nomura Instinet
Revolve Group initiated with a Neutral at Nomura Instinet
BRP BRP Group
$8.99 /

-1.01 (-10.10%)

03/26/20 Keefe Bruyette
BRP Group price target lowered to $16 from $22 at Keefe Bruyette
02/21/20 Northcoast
BRP Group downgraded to Neutral from Buy at Northcoast
11/18/19
Fly Intel: Top five analyst initiations
11/18/19 Jefferies
BRP Group initiated with a Hold at Jefferies
JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

12/13/19 Jefferies
Removal, delay of China tariffs give 'reprieve' to toy companies, says Jefferies
RKDA Arcadia Biosciences
$4.88 /

+0.15 (+3.17%)

06/06/19 H.C. Wainwright
Arcadia Biosciences price target lowered to $14 from $20 at H.C. Wainwright
VRTU Virtusa
$31.75 /

-1.95 (-5.79%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

RKDA Arcadia Biosciences
$4.88 /

+0.15 (+3.17%)

PANL Pangaea Logistics
$2.30 /

-0.03 (-1.29%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

OII Oceaneering
$4.64 /

-0.26 (-5.31%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

FLO Flowers Foods
$22.64 /

+0.17 (+0.76%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

BRP BRP Group
$8.99 /

-1.01 (-10.10%)

ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

  • 14
    May
SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

OII Oceaneering
$4.64 /

-0.26 (-5.31%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

KNSA Kiniksa
$18.97 /

-2.13 (-10.09%)

JAKK JAKKS Pacific
$0.59 /

-0.0939 (-13.81%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

IMUX Immunic
$10.00 /

-0.72 (-6.72%)

IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

ARVN Arvinas
$51.00 /

-4.4 (-7.94%)

ALLO Allogene Therapeutics
$30.99 /

-1.56 (-4.79%)

SDC SmileDirectClub
$7.70 /

-0.39 (-4.82%)

RVLV Revolve Group
$14.92 /

+0.49 (+3.40%)

ONEM 1Life Healthcare
$26.78 /

-0.44 (-1.62%)

MA MasterCard
$269.58 /

-2.66 (-0.98%)

JACK Jack in the Box
$63.59 /

-2.29 (-3.48%)

FCAU Fiat Chrysler
$7.90 /

-0.27 (-3.30%)

CSCO Cisco
$41.91 /

-1.28 (-2.96%)

Hot Stocks
ImmunoGen reports initial data from FORWARD II study » 17:04
05/13/20
05/13
17:04
05/13/20
17:04
IMGN

ImmunoGen

$4.09 /

-0.19 (-4.44%)

ImmunoGen announced…

ImmunoGen announced initial data from the FORWARD II study evaluating mirvetuximab soravtansine in combination with Avastin in patients with medium and high folate receptor alpha (FRalpha)-expressing recurrent ovarian cancer for whom a non-platinum based combination regimen is appropriate. These findings will be highlighted in an oral presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program on May 29, 2020. Three "trial in progress" posters will also be presented during the meeting. "With the benefit of the clinical profile demonstrated by mirvetuximab monotherapy, we have pursued a development strategy to establish mirvetuximab as the agent of choice in combination regimens to treat expanded populations of patients with recurrent ovarian cancer. To this end, we are encouraged by the compelling anti-tumor activity and favorable tolerability observed with the combination of mirvetuximab plus bevacizumab in patients for whom a non-platinum based regimen is appropriate," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen. "These findings show greater depth and duration of tumor reduction in women whose tumors express high levels of FRalpha, regardless of platinum status, reinforcing the potential of this doublet in these patients. As these data mature, we look forward to further evaluating this combination in the recurrent ovarian cancer setting." This cohort enrolled 60 patients with FRalpha-positive recurrent ovarian cancer for whom a non-platinum based combination regimen is appropriate, with a median age of 60 years and a median number of 2 prior lines of therapy. The combination of mirvetuximab soravtansine with bevacizumab in this cohort demonstrates encouraging anti-tumor activity with a favorable tolerability profile, particularly among the subset of patients with high levels of FRalpha expression. Key findings include: In the overall patient population, objective responses were seen in 26 patients and the confirmed overall response rate was 43%; In patients with high FRalpha expression, the confirmed ORR was 61%, with an ORR of at least 50% in each of the platinum-resistant and platinum-sensitive subgroups; With many patients remaining on study, the duration of response and progression free survival data are immature; Te adverse events observed with the doublet were as expected based on the side effect profiles of each agent. The most common treatment-related low grade AEs were diarrhea, blurred vision, nausea, and fatigue; grade 3+ AEs were infrequent, with the most common being hypertension and neutropenia.

ShowHide Related Items >><<
IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

IMGN ImmunoGen
$4.09 /

-0.19 (-4.44%)

Recommendations
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright » 07:15
05/04/20
05/04
07:15
05/04/20
07:15
IMGN

ImmunoGen

$3.74 /

-0.33 (-8.11%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Debjit Chattopadhyay says shares of ImmunoGen offer a "compelling entry point" with its clinical catalyst calendar "turning favorable." The safety, activity, and combinability data generated by mirvetuximab positions the asset ahead of relevant competition, Chattopadhyay tells investors in a research note. The analyst sees a favorable clinical catalyst calendar and keeps a Buy rating on ImmunoGen with a $9 price target.

ShowHide Related Items >><<
IMGN ImmunoGen
$3.74 /

-0.33 (-8.11%)

12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
05/15/19 Guggenheim
ImmunoGen downgraded to Neutral from Buy at Guggenheim
Earnings
ImmunoGen backs 2020 revenue view $60M-$65M, consensus $62.72M » 06:33
05/01/20
05/01
06:33
05/01/20
06:33
IMGN

ImmunoGen

$4.07 /

+ (+0.00%)

Sees 2020 operating…

Sees 2020 operating expenses $165M-$170M; and cash and cash equivalents at December 31 $170M-$175M.

ShowHide Related Items >><<
IMGN ImmunoGen
$4.07 /

+ (+0.00%)

12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
05/15/19 Guggenheim
ImmunoGen downgraded to Neutral from Buy at Guggenheim
Earnings
ImmunoGen reports Q1 EPS (17c), consensus (15c) » 06:32
05/01/20
05/01
06:32
05/01/20
06:32
IMGN

ImmunoGen

$4.07 /

+ (+0.00%)

Reports Q1 revenue…

Reports Q1 revenue $13.3M, consensus $14.94M. CEO Mark Enyedy said, "Our lead program remains on track with the initiation of our pivotal SORAYA trial and patient enrollment in our confirmatory MIRASOL trial progressing as anticipated. In parallel, we continue to follow our FORWARD II combination cohorts and we are pleased to have initial data from our Avastin expansion cohort in platinum-agnostic ovarian cancer selected for a virtual oral presentation at ASCO in May. IND-enabling activities for IMGC936, our novel ADAM9-targeting ADC, continue on plan with an IND submission anticipated by the end of this quarter and we look forward to presenting pre-clinical data on IMGN151, our next generation anti-FRalpha ADC being investigated in tumors with a broad range of FRalpha expression, at the virtual AACR Annual Meeting in June. Having generated approximately $98M in net proceeds through a follow-on offering in January, we are in a strong financial position with our anticipated cash runway extended well into 2022".

ShowHide Related Items >><<
IMGN ImmunoGen
$4.07 /

+ (+0.00%)

12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
05/15/19 Guggenheim
ImmunoGen downgraded to Neutral from Buy at Guggenheim
Over a quarter ago
Conference/Events
Cowen to hold a conference » 04:55
03/04/20
03/04
04:55
03/04/20
04:55
A

Agilent

$80.44 /

-1.54 (-1.88%)

, ABBV

AbbVie

$87.57 /

-1.03 (-1.16%)

, ADRO

Aduro Biotech

$3.04 /

+ (+0.00%)

, ALXN

Alexion

$93.85 /

-2.08 (-2.17%)

, BBIO

BridgeBio

$32.37 /

+0.17 (+0.53%)

, CTMX

CytomX Therapeutics

$7.28 /

+0.18 (+2.54%)

, EPZM

Epizyme

$20.71 /

-2.33 (-10.11%)

, FOMX

Foamix

$3.35 /

-0.095 (-2.76%)

, IMGN

ImmunoGen

$4.39 /

-0.02 (-0.45%)

, LLY

Eli Lilly

$130.32 /

-2.24 (-1.69%)

, MORF

Morphic Holding

$15.78 /

-0.18 (-1.13%)

, MSON

Misonix

$13.87 /

+0.01 (+0.07%)

, JNJ

Johnson & Johnson

$135.71 /

-4.28 (-3.06%)

, HZNP

Horizon Therapeutics

$34.39 /

-0.72 (-2.05%)

, GILD

Gilead

$74.26 /

-1.14 (-1.51%)

, EW

Edwards Lifesciences

$209.03 /

-3.4 (-1.60%)

, DVAX

Dynavax

$4.25 /

-0.23 (-5.13%)

, BSX

Boston Scientific

$37.22 /

-1.01 (-2.64%)

, BMRN

BioMarin

$92.66 /

-1.81 (-1.92%)

, BLUE

Bluebird Bio

$71.14 /

-2.75 (-3.72%)

, BIIB

Biogen

$315.79 /

-12.18 (-3.71%)

, CERS

Cerus

$5.02 /

-0.08 (-1.57%)

, HARP

Harpoon Therapeutics

$15.70 /

-0.56 (-3.44%)

, IRWD

Ironwood

$12.24 /

-0.44 (-3.47%)

, JAZZ

Jazz Pharmaceuticals

$115.32 /

-9.64 (-7.71%)

, MRNA

Moderna

$27.91 /

-1.965 (-6.58%)

, ZTS

Zoetis

$137.33 /

-1.56 (-1.12%)

, XOMA

Xoma

$24.48 /

-0.52 (-2.08%)

, TECH

Bio-Techne

$193.46 /

-3.94 (-2.00%)

, TMO

Thermo Fisher

$310.46 /

+5.76 (+1.89%)

, SEEL

Seelos Therapeutics

$0.87 /

-0.0238 (-2.67%)

, PIRS

Pieris Pharmaceuticals

$3.16 /

-0.13 (-3.95%)

, PFE

Pfizer

$34.27 /

-0.62 (-1.78%)

, PBYI

Puma Biotechnology

$10.42 /

-0.25 (-2.34%)

, NLTX

Neoleukin Therapeutics

$10.59 /

-0.03 (-0.28%)

, OXFD

Oxford Immunotec

$13.21 /

-0.1 (-0.75%)

, RYTM

Rhythm Pharmaceuticals

$19.59 /

-0.83 (-4.06%)

40th Annual Healthcare…

40th Annual Healthcare Conference will be held in Boston on March 2-4.

ShowHide Related Items >><<
A Agilent
$80.44 /

-1.54 (-1.88%)

02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
02/06/20 Cowen
Developments in Agilent-Twist dispute could mean settlement imminent, says Cowen
ABBV AbbVie
$87.57 /

-1.03 (-1.16%)

02/27/20 Barclays
AbbVie initiated with an Equal Weight at Barclays
02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
ADRO Aduro Biotech
$3.04 /

+ (+0.00%)

01/10/20 Cowen
Aduro downgraded to Market Perform on limited visibility at Cowen
01/10/20 Cowen
Aduro Biotech downgraded to Market Perform from Outperform at Cowen
12/18/19 H.C. Wainwright
Aduro Biotech price target lowered to $4 from $7 at H.C. Wainwright
12/18/19 William Blair
Aduro Biotech downgraded to Market Perform from Outperform at William Blair
ALXN Alexion
$93.85 /

-2.08 (-2.17%)

02/25/20 Citi
Alexion loses catalyst with removal of ABY-039, says Citi
02/03/20 Nomura Instinet
Alexion price target lowered to $133 from $165 at Nomura Instinet
01/31/20 Baird
Alexion price target lowered to $140 from $165 at Baird
01/31/20 RBC Capital
Alexion reinstated with Outperform rating after Achillion acquisition
BBIO BridgeBio
$32.37 /

+0.17 (+0.53%)

02/19/20
Fly Intel: Top five analyst initiations
02/19/20 Mizuho
Mizuho starts BridgeBio with Buy rating, $51 price target
02/18/20 Mizuho
BridgeBio initiated with a Buy at Mizuho
01/07/20 Raymond James
BridgeBio price target raised to $40 from $36 at Raymond James
CTMX CytomX Therapeutics
$7.28 /

+0.18 (+2.54%)

02/27/20 Piper Sandler
CytomX Therapeutics heading for platform validation, says Piper Sandler
02/24/20 H.C. Wainwright
CytomX partner's Phase 2 initiation triggers milestone, says H.C. Wainwright
11/20/19 Guggenheim
Guggenheim starts CytomX Therapeutics with Buy rating, $16 price target
11/19/19 Guggenheim
CytomX Therapeutics initiated with a Buy at Guggenheim
EPZM Epizyme
$20.71 /

-2.33 (-10.11%)

02/25/20 H.C. Wainwright
Epizyme price target raised to $36 from $25 at H.C. Wainwright
02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
01/24/20 Cowen
Epizyme price target raised to $36 from $18 at Cowen
01/24/20 SVB Leerink
SVB Leerink moving to the sidelines on Epizyme after Tazverik approval
FOMX Foamix
$3.35 /

-0.095 (-2.76%)

10/21/19 H.C. Wainwright
Foamix price target raised to $11 from $10 at H.C. Wainwright
10/16/19 Barclays
Barclays likes Foamix setup into October 20 FDA action date
10/08/19 Cantor Fitzgerald
Cantor reiterates Overweight on Foamix ahead of FMX101 PDUFA
06/11/19 Barclays
Foamix initiated with an Overweight at Barclays
IMGN ImmunoGen
$4.39 /

-0.02 (-0.45%)

12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
05/15/19 Guggenheim
ImmunoGen downgraded to Neutral from Buy at Guggenheim
LLY Eli Lilly
$130.32 /

-2.24 (-1.69%)

02/27/20 Barclays
Eli Lilly initiated with an Overweight at Barclays
02/18/20 Piper Sandler
Xeris Pharmaceuticals initiated with an Overweight at Piper Sandler
02/10/20 William Blair
William Blair sees little change to sentiment for aducanumab after DIAN-TU fails
02/05/20 Mizuho
Eli Lilly initiated with a Neutral at Mizuho
MORF Morphic Holding
$15.78 /

-0.18 (-1.13%)

07/22/19 Jefferies
Morphic Holding initiated with a Buy at Jefferies
07/22/19 Wells Fargo
Morphic Holding initiated with an Outperform at Wells Fargo
07/22/19 BMO Capital
Morphic Holding initiated with an Outperform at BMO Capital
MSON Misonix
$13.87 /

+0.01 (+0.07%)

12/31/19 Craig-Hallum
Misonix's amended credit line removes capital needs questions, says Craig-Hallum
08/15/19 Canaccord
Misonix price target raised to $30 from $24 at Canaccord
06/12/19
Fly Intel: Top five analyst initiations
06/12/19 BTIG
Misonix initiated with a Buy at BTIG
JNJ Johnson & Johnson
$135.71 /

-4.28 (-3.06%)

03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
01/27/20 Credit Suisse
Johnson & Johnson price target raised to $170 from $163 at Credit Suisse
01/21/20 SVB Leerink
SVB Leerink bearish on Arrowhead, initiates with an Underperform
01/10/20 BWS Financial
Anika acquisitions set up direct competition with partner, says BWS Financial
HZNP Horizon Therapeutics
$34.39 /

-0.72 (-2.05%)

02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
01/22/20 BMO Capital
Horizon Therapeutics price target raised to $46 from $40 at BMO Capita
01/22/20 Guggenheim
Horizon's label for Tepezza 'broad and incredibly clean,' says Guggenheim
01/14/20 JMP Securities
Horizon Therapeutics price target raised to $47 from $38 at JMP Securities
GILD Gilead
$74.26 /

-1.14 (-1.51%)

03/03/20 Canaccord
Forty Seven downgraded to Hold from Buy at Canaccord
03/02/20 H.C. Wainwright
Forty Seven downgraded to Neutral from Buy at H.C. Wainwright
03/02/20 Roth Capital
Forty Seven downgraded to Neutral from Buy at Roth Capital
02/28/20 Benchmark
Ligand a 'coronavirus play in the making,' says Benchmark
EW Edwards Lifesciences
$209.03 /

-3.4 (-1.60%)

02/12/20 Goldman Sachs
Edwards Lifesciences initiated with a Neutral at Goldman Sachs
01/31/20 Piper Sandler
Edwards Lifesciences price target raised to $270 from $262 at Piper Sandler
01/10/20 Wells Fargo
Wells says PTAB ruling of 'zero importance' to bigger Abbott-Edwards fight
01/10/20
Fly Intel: Top five analyst upgrades
DVAX Dynavax
$4.25 /

-0.23 (-5.13%)

10/18/19 H.C. Wainwright
Dynavax initiated with a Buy at H.C. Wainwright
07/10/19 Cantor Fitzgerald
Dynavax upgraded to Overweight from Neutral at Cantor Fitzgerald
06/18/19 BMO Capital
VBI Vaccines price target lowered to $5 from $12 at BMO Capital
05/24/19 RBC Capital
Dynavax price target lowered to $13 from $19 at RBC Capital
BSX Boston Scientific
$37.22 /

-1.01 (-2.64%)

03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
02/12/20 Goldman Sachs
Boston Scientific initiated with a Neutral at Goldman Sachs
02/05/20 Piper Sandler
Piper Sandler constructive on Boston Scientific given guidance, new product flow
01/17/20 Piper Sandler
FDA recommendation a 'solid tailwind' for Boston Scientific, says Piper Sandler
BMRN BioMarin
$92.66 /

-1.81 (-1.92%)

03/02/20 Wedbush
BioMarin price target lowered to $164 from $175 at Wedbush
02/28/20 Citi
BioMarin price target raised to $105 from $95 at Citi
02/27/20 Oppenheimer
BioMarin price target raised to $88 from $80 at Oppenheimer
02/26/20 Piper Sandler
BioMarin firing on all cylinders, says Piper Sandler
BLUE Bluebird Bio
$71.14 /

-2.75 (-3.72%)

02/20/20 Oppenheimer
Bluebird Bio price target lowered to $128 from $135 at Oppenheimer
02/19/20 Raymond James
Bluebird Bio downgraded to Market Perform from Strong Buy at Raymond James
02/19/20 Piper Sandler
Bluebird pushed Biologics License Application to second half, says Piper Sandler
02/03/20 Evercore ISI
Bluebird Bio upgraded to Outperform on undervalued assets at Evercore ISI
BIIB Biogen
$315.79 /

-12.18 (-3.71%)

02/28/20 William Blair
Biogen deal with Sangamo unlikely to have near-term impact, says William Blair
02/27/20 Barclays
Biogen initiated with an Overweight at Barclays
02/24/20 Jefferies
Jefferies starts Denali Therapeutics at Buy ahead of 'lots of catalysts in 2020'
CERS Cerus
$5.02 /

-0.08 (-1.57%)

02/26/20 BTIG
Cerus initiated with a Buy at BTIG
01/23/20 Cowen
Cowen encouraged by Cerus data on Intercept in light of new coronavirus
11/13/19 BTIG
Cerus upgraded to Buy from Neutral at BTIG
08/28/19
Fly Intel: Top five analyst initiations
HARP Harpoon Therapeutics
$15.70 /

-0.56 (-3.44%)

02/28/20
Fly Intel: Top five analyst initiations
02/27/20 SunTrust
Harpoon Therapeutics initiated with a Buy at SunTrust
02/03/20
Fly Intel: Top five analyst initiations
02/03/20 H.C. Wainwright
Harpoon Therapeutics initiated with a Buy at H.C. Wainwright
IRWD Ironwood
$12.24 /

-0.44 (-3.47%)

08/05/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
07/10/19 Credit Suisse
Ironwood assumed with a Neutral at Credit Suisse
03/27/19 Morgan Stanley
Morgan Stanley upgrades Ironwood to Equal Weight on more stable Linzess growth
03/27/19 Morgan Stanley
Ironwood upgraded to Equal Weight from Underweight at Morgan Stanley
JAZZ Jazz Pharmaceuticals
$115.32 /

-9.64 (-7.71%)

02/26/20 RBC Capital
Jazz Pharmaceuticals price target lowered to $164 from $184 at RBC Capital
02/26/20 Oppenheimer
Jazz Pharmaceuticals price target lowered to $154 from $183 at Oppenheimer
02/26/20 Cowen
Jazz Pharmaceuticals lowered his price target to $165 from $200 at Cowen
02/26/20 Piper Sandler
Jazz Pharmaceuticals price target lowered to $129 from $142 at Piper Sandler
MRNA Moderna
$27.91 /

-1.965 (-6.58%)

02/28/20 Piper Sandler
Moderna has five potential mRNA rare disease blockbusters, says Piper Sandler
02/27/20 JPMorgan
Moderna price target raised to $32 from $24 at JPMorgan
02/27/20 Roth Capital
Moderna price target raised to $33 from $24 at Roth Capital
02/26/20 Piper Sandler
Piper Sandler backs rating on Moderna after coronavirus vaccine shipped
ZTS Zoetis
$137.33 /

-1.56 (-1.12%)

02/14/20 SunTrust
Zoetis price target raised to $145 from $130 at SunTrust
01/10/20 Raymond James
Zoetis' premium valuation vs. peers likely to persist, says Raymond James
01/09/20 Raymond James
Zoetis initiated with a Market Perform at Raymond James
12/19/19 BofA
Elanco upgraded to Buy from Neutral at BofA/Merrill
XOMA Xoma
$24.48 /

-0.52 (-2.08%)

TECH Bio-Techne
$193.46 /

-3.94 (-2.00%)

02/24/20 Eight Capital
Bio-Techne downgraded to Neutral from Buy at Eight Capital
01/08/20 Stephens
Bio-Techne resumed with an Overweight at Stephens
01/07/20 Wells Fargo
Bio-Techne initiated with an Equal Weight at Wells Fargo
01/06/20 Citi
Bio-Techne initiated with a Neutral at Citi
TMO Thermo Fisher
$310.46 /

+5.76 (+1.89%)

03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/24/20 Argus
Thermo Fisher price target raised to $370 from $340 at Argus
01/31/20 BTIG
Thermo Fisher price target raised to $372 from $342 at BTIG
SEEL Seelos Therapeutics
$0.87 /

-0.0238 (-2.67%)

11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
11/14/19 Benchmark
Seelos Therapeutics initiated with a Speculative Buy at Benchmark
05/14/19 Roth Capital
Seelos Therapeutics initiated with a Buy at Roth Capital
05/10/19 H.C. Wainwright
Seelos Therapeutics initiated with a Buy at H.C. Wainwright
PIRS Pieris Pharmaceuticals
$3.16 /

-0.13 (-3.95%)

01/27/20 H.C. Wainwright
Pieris Pharmaceuticals price target raised to $9 from $7 at H.C. Wainwright
07/30/19 Baird
Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird
07/29/19 William Blair
Updates 'very positive' for upcoming Pieris presentation, says William Blair
05/14/19 Baird
Pieris Pharmaceuticals initiated with an Outperform at Baird
PFE Pfizer
$34.27 /

-0.62 (-1.78%)

02/27/20 Standpoint Research
Pfizer upgraded to Buy from Hold at Standpoint Research
02/27/20 Barclays
Pfizer initiated with an Equal Weight at Barclays
02/12/20 Baird
Exact Sciences weakness would be buying opportunity, says Baird
02/11/20 Roth Capital
GlycoMimetics termination notice from Pfizer no surprise, says Roth Capital
PBYI Puma Biotechnology
$10.42 /

-0.25 (-2.34%)

12/06/19 H.C. Wainwright
Puma Biotechnology initiated with a Buy at H.C. Wainwright
11/08/19 Cantor Fitzgerald
Puma Biotechnology price target lowered to $14 from $20 at Cantor Fitzgerald
11/07/19 RBC Capital
Puma Biotechnology price target lowered to $13 from $23 at RBC Capital
11/07/19 Barclays
Puma Biotechnology price target lowered to $6 from $9 at Barclays
NLTX Neoleukin Therapeutics
$10.59 /

-0.03 (-0.28%)

02/18/20
Fly Intel: Top five analyst initiations
02/18/20 Guggenheim
Guggenheim starts Neoleukin Therapeutics at Buy with $20 price target
02/18/20 Guggenheim
Neoleukin Therapeutics initiated with a Buy at Guggenheim
01/10/20 Piper Sandler
Neoleukin Therapeutics initiated with an Overweight at Piper Sandler
OXFD Oxford Immunotec
$13.21 /

-0.1 (-0.75%)

09/24/19 Cowen
Oxford Immunotec company sale may make sense, says Cowen
09/18/19 Piper Sandler
Oxford Immunotec's new approach to China could boost sales, says Piper Jaffray
03/12/19 Baird
Oxford Immunotec's 2019 guidance seems 'conservative,' says Baird
03/12/19 Piper Sandler
Oxford Immunotec well positioned for strong 2019 transition, says Piper Jaffray
RYTM Rhythm Pharmaceuticals
$19.59 /

-0.83 (-4.06%)

01/08/20 Goldman Sachs
Rhythm Pharmaceuticals initiated with a Sell at Goldman Sachs
07/12/19 Stifel
Rhythm Pharmaceuticals upgraded to Buy from Hold at Stifel
03/13/19
Fly Intel: Top five analyst initiations
03/13/19 Ladenburg
Ladenburg starts Rhythm Pharmaceuticals with Buy rating, $43 price target

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.